Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
Key Highlights
- ➤Intellia appoints Jing L. Marantz chief medical officer, effective October 26, 2026
- ➤Marantz will lead translational, development, regulatory and medical affairs functions
- ➤Intellia targets commercializing lonvo-z, advancing Phase 3 nex-z trials, and expanding its pipeline
Expert Statements
John Leonard, M.D., President and Chief Executive Officer of Intellia Therapeutics
“Jing is an exceptional leader with a track record of success in the rare disease space across the full lifecycle from development through regulatory approval and commercialization”
John Leonard, M.D., President and Chief Executive Officer of Intellia Therapeutics
“We are delighted to welcome her as our Chief Medical Officer during this exciting and momentous time at Intellia. Her unique combination of development and business experience will be critical for our next phase as we seek to commercialize our first potential in vivo gene editing product, advance our Phase 3 clinical trials in transthyretin amyloidosis and further expand our pipeline.”
Jing L. Marantz, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Intellia Therapeutics
“I am thrilled to join Intellia, where we have the opportunity to profoundly improve patient lives by delivering durable efficacy while minimizing treatment burden leveraging Nobel-prize-winning science.”
Jing L. Marantz, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Intellia Therapeutics
“I look forward to working with the company’s talented team to advance our clinical programs with the goal of bringing new therapeutic options to patients with serious diseases.”
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company’s translational, development, regulatory and medical affairs functions.
“Jing is an exceptional leader with a track record of success in the rare disease space across the full lifecycle from development through regulatory approval and commercialization,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “We are delighted to welcome her as our Chief Medical Officer during this exciting and momentous time at Intellia. Her unique combination of development and business experience will be critical for our next phase as we seek to commercialize our first potential in vivo gene editing product, advance our Phase 3 clinical trials in transthyretin amyloidosis and further expand our pipeline.”
Get started
Create a free account to read the full story.